What are the baseline characteristics of patients with early-stage type 2 diabetes when treated with SGLT2 inhibitors versus metformin?

Zenodo (CERN European Organization for Nuclear Research) 2026 Open access

Read full text
Authors: Tripdatabase
DOI: 10.5281/zenodo.18470612
Cited by: 0

Abstract

Patients with early-stage type 2 diabetes treated with SGLT2 inhibitors and metformin share similarities in glycemic control and modest comorbidities, though population characteristics such as age, ethnicity, and disease duration vary among studies.

Fields of Study & Subjects

Diabetes Treatment and Management Diabetes Management and Research Heart Failure Treatment and Management

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
3 February 2026